IP Library Granted Patent US 7,288,578
Granted Patent B2
US 7,288,578 · App. 10/676,764 · Granted Oct 30, 2007

Biocompatible inks, preparation, and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,288,578
App. No.
10/676,764
Granted
Oct 30, 2007
Kind
B2
Abstract

An aqueous ink comprising containing a colorant and a radiation-curable oligomer or polymer containing H-active groups bonded to the oligomer or polymer backbone, some or all of whose hydrogen atoms have been substituted by radicals of a N-hydroxyalkyl (meth)acrylamide. Methods for printing the inventive inks upon medical devices, such as contact lenses, are also disclosed.

Claims (19)

1. An ink comprising

a. water;

b. at least one colorant including pigment particles;

c. ink binders including an acrylate-modified poly(vinyl alcohol) and a radiation-curable (meth)acrylamidoalkyl derivative of an oligomer or polymer containing a plurality of H-active groups;

wherein the radiation-curable (meth)acrylamidoalkyl derivative is added in the ink in an amount sufficient to provide the ink a desired viscosity for ink-jet printing or pad-printing while still being able to hold together and properly bind the ink to an ophthalmic lens onto which the ink is applied.

2. An ink as claimed in claim 1 , wherein said H-active groups are selected from the group consisting of —NH 2 groups and —OH groups.

3. An ink as claimed in claim 1 , wherein said (meth)acrylamidoalkyl derivative is obtained by substituting at least one hydrogen atom in H-active groups of the oligomer or polymer with radicals of a N-hydroxyalkyl (meth)acrylamide of the structure

wherein R 1 is methyl or —H; R 2 is —[(CH 2 ) x —O—] y —H, where x is 1,2, or 3 and y is 1-5.

4. An ink as claimed in claim 3 , wherein the N-hydroxyalkyl (meth)acrylamide is selected from the group consisting of N-2-hydroxylethyl acrylamide, N-2-hydroxyethyl methacrylamide, N-methylol acrylamide, and N-methylol methacrylamide.

5. An ink as claimed in claim 2 , wherein said polymer is selected from the group consisting of polysaccharides, polysaccharide derivatives, poly(ethylene glycol), poly(propylene oxide), PEG-block-PPO, poly(acrylamide), and copolymers thereof.

6. An ink as claimed in claim 5 , wherein said polymer is selected from the group consisting of dextran, hydroxypropylcellulose, hydroxyethylcellulose, and polysaccharides comprising glucose monosaccharide units.

7. An ink as claimed in claim 1 , wherein said polymer is dextran and said N-hydroxyalkyl (meth)acrylamide is N-methylol acrylamide.

8. An ink as claimed in claim 2 , wherein said (meth)acrylamidoalkyl derivative is obtained by substituting at least one hydrogen atom in H-active groups of the oligomer or polymer with radicals of a N-hydroxyalkyl (meth)acrylamide of the structure

wherein R 1 is methyl or —H; R 2 is —[(CH 2 ) x —O—]—H, where x is 1,2, or 3 and y is 1-5.

9. An ink as claimed in claim 8 , wherein the N-hydroxyalkyl (meth)acrylamide is selected from the group consisting of N-2-hydroxylethyl acrylamide, N-2-hydroxyethyl methacrylamide, N-methylol acrylamide, and N-methylol methacrylamide.

10. An ink as claimed in claim 3 , wherein said polymer is selected from the group consisting of polysaccharides, polysaccharide derivatives, poly(ethylene glycol), poly(propylene oxide), PEG-block-PPO, poly(acrylamide), and copolymers thereof.

11. An ink as claimed in claim 10 , wherein said polymer is selected from the group consisting of dextran, hydroxypropylcellulose, hydroxyethylcellulose, and polysaccharides comprising glucose monosaccharide units.

12. An ink as claimed in claim 2 , wherein said polymer is dextran and said N-hydroxyalkyl (meth)acrylamide is N-methylol acrylamide.

13. An ink as claimed in claim 3 , wherein said polymer is dextran and said N-hydroxyalkyl (meth)acrylamide is N-methylol acrylamide.

Assignments (1)
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Dec 10, 2019
From: NOVARTIS AG
To: ALCON INC.
Reel/Frame 051454/0788 →